Javascript must be enabled to continue!
PS1275 INVASIVE ASPERGILLOSIS CAUSED BY ”RARE“ PATHOGENS: CLINICAL REGISTRY DATA ANALYSIS
View through CrossRef
Background:Publications describing invasive aspergillosis (IA) caused by “rare” pathogens are limited. Species identification of the pathogen is necessary for the selection of antifungal therapy, as some Aspergillus spp. may be resistant to antifungal drugs.Aims:Analysis clinical registry data of patients with IA caused by “rare” pathogensMethods:Retrospective analysis of patients with IA caused by “rare” pathogens in 1998–2019 yy. For the IA diagnosis EORTC / MSD, 2008 criteria were used. In accordance with the European guidelines, DNA sequencing and MALDI‐TOF were used to identify of the “rare” Aspergillus spp.Results:In our registry we included 800 patients with IA. In 227 patients Aspergillus spp. were isolated. The “rare” pathogens were detected in 18 (8%), and these patients were included in group I; age varied from 5 to 67 years, median – 40.5,males – 50%. The control group consisted 209 patients with other Aspergillus spp. (A. fumigatus,A. niger and A. flavus), from 1 to 99 years old, median ‐ 47, males – 53%. In both groups IA predominantly occurs in patients with hematologic malignancies (73% vs 76%): acute leukemia – 27% vs 33%, lymphoma – 22% vs 27%, multiple myeloma 12% vs 6%, chronic leukemia 6% in each group, other hematological diseases – 6% vs 4%. We identified, IA caused by ”rare“ pathogens more often developed in children(22% vs 11%, p < 0.05).In addition to standard risk factors, in patients with ”rare“ pathogens more often was detected lymphocytopenia 67% vs 55%, with duration 21 vs 14 days, p < 0.05, less frequent was noted fever (46% vs 78%, p < 0.05), but significantly more lung damage accompanied by hemoptysis (17% vs 10%, p < 0.05). “Rare” pathogens were A. ustus – 38%, A. nidulans – 22%, A. calidoustus – 8%,A. versicolor– 8%,A.glaucus – 8%,A. candidus – 8%, andA. sydowii – 8%. In controlgroup etiological agents were A. fumigatus – 52%,A. niger – 31%, A. flavus– 17%. Two or more species of Aspergillus were isolated in 44% vs 9%, p < 0.05. Antifungal therapy was used in 100% vs 97% of patients. Twelve weeks overall survival rate was 82% vs 81%. In the group with “rare” pathogens more frequently observed relapse of IA – 33% vs 12%, p <0.05.Summary/Conclusion:Patients with “rare” pathogens account for 8% of patients with isolated Aspergillus spp. cultures. IA caused by ”rare“ pathogens, more often occurs in children – 22%. The features of IA caused by “rare” pathogens are: long‐term lymphocytopenia (67%, median ‐ 21 days), combination of two or more pathogens – 44%, high relapse rate – 33%. Survival of patients with “rare” pathogens does not differ from the total cohort of patients – 82%.
Title: PS1275 INVASIVE ASPERGILLOSIS CAUSED BY ”RARE“ PATHOGENS: CLINICAL REGISTRY DATA ANALYSIS
Description:
Background:Publications describing invasive aspergillosis (IA) caused by “rare” pathogens are limited.
Species identification of the pathogen is necessary for the selection of antifungal therapy, as some Aspergillus spp.
may be resistant to antifungal drugs.
Aims:Analysis clinical registry data of patients with IA caused by “rare” pathogensMethods:Retrospective analysis of patients with IA caused by “rare” pathogens in 1998–2019 yy.
For the IA diagnosis EORTC / MSD, 2008 criteria were used.
In accordance with the European guidelines, DNA sequencing and MALDI‐TOF were used to identify of the “rare” Aspergillus spp.
Results:In our registry we included 800 patients with IA.
In 227 patients Aspergillus spp.
were isolated.
The “rare” pathogens were detected in 18 (8%), and these patients were included in group I; age varied from 5 to 67 years, median – 40.
5,males – 50%.
The control group consisted 209 patients with other Aspergillus spp.
(A.
fumigatus,A.
niger and A.
flavus), from 1 to 99 years old, median ‐ 47, males – 53%.
In both groups IA predominantly occurs in patients with hematologic malignancies (73% vs 76%): acute leukemia – 27% vs 33%, lymphoma – 22% vs 27%, multiple myeloma 12% vs 6%, chronic leukemia 6% in each group, other hematological diseases – 6% vs 4%.
We identified, IA caused by ”rare“ pathogens more often developed in children(22% vs 11%, p < 0.
05).
In addition to standard risk factors, in patients with ”rare“ pathogens more often was detected lymphocytopenia 67% vs 55%, with duration 21 vs 14 days, p < 0.
05, less frequent was noted fever (46% vs 78%, p < 0.
05), but significantly more lung damage accompanied by hemoptysis (17% vs 10%, p < 0.
05).
“Rare” pathogens were A.
ustus – 38%, A.
nidulans – 22%, A.
calidoustus – 8%,A.
versicolor– 8%,A.
glaucus – 8%,A.
candidus – 8%, andA.
sydowii – 8%.
In controlgroup etiological agents were A.
fumigatus – 52%,A.
niger – 31%, A.
flavus– 17%.
Two or more species of Aspergillus were isolated in 44% vs 9%, p < 0.
05.
Antifungal therapy was used in 100% vs 97% of patients.
Twelve weeks overall survival rate was 82% vs 81%.
In the group with “rare” pathogens more frequently observed relapse of IA – 33% vs 12%, p <0.
05.
Summary/Conclusion:Patients with “rare” pathogens account for 8% of patients with isolated Aspergillus spp.
cultures.
IA caused by ”rare“ pathogens, more often occurs in children – 22%.
The features of IA caused by “rare” pathogens are: long‐term lymphocytopenia (67%, median ‐ 21 days), combination of two or more pathogens – 44%, high relapse rate – 33%.
Survival of patients with “rare” pathogens does not differ from the total cohort of patients – 82%.
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Aspergillosis in Chronic Granulomatous Disease
Aspergillosis in Chronic Granulomatous Disease
Patients with chronic granulomatous disease (CGD) have the highest life-time incidence of invasive aspergillosis and despite the availability of antifungal prophylaxis, infections ...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Abstract OT-11-01: The informed genetics annotated patient registry: The iGAP registry
Abstract OT-11-01: The informed genetics annotated patient registry: The iGAP registry
Abstract
Background
Interest and knowledge about the genetics and biology of inherited risk of and progression of disease is growing. Physicians are i...
Assessment of Invasive Species Severity along the Nature Trail at the Doi Chiang Dao Biosphere Reserve, Chiang Mai Province
Assessment of Invasive Species Severity along the Nature Trail at the Doi Chiang Dao Biosphere Reserve, Chiang Mai Province
Background and Objectives: Doi Chiang Dao Biosphere Reserve has been officially declared as the fifth Biosphere Reserve of Thailand, representing a critically important terrestrial...
Update on the treatment of chronic pulmonary aspergillosis
Update on the treatment of chronic pulmonary aspergillosis
Purpose of review
Chronic pulmonary aspergillosis is a major global infection in individuals with preexisting structural lung diseases and those with immunodeficiencies...
The state of cancer care in Russia. Analytical indicators: one-year mortality (population study at the federal district level)
The state of cancer care in Russia. Analytical indicators: one-year mortality (population study at the federal district level)
In February 2019, Russia's first Population-based Cancer Registry (PCR) was created at the federal district level with a database of more than 1 million 350 thousand obser...
Registry-Based Randomized Controlled Trials: Conduct, Advantages and Challenges – A Systematic Review.
Registry-Based Randomized Controlled Trials: Conduct, Advantages and Challenges – A Systematic Review.
Abstract
Background: Registry-based Randomized Controlled Trials (rRCTs) have been described as pragmatic studies utilising patient data embedded in large scale registries,...

